Sage Therapeutics (NASDAQ:SAGE) Announces Earnings Results

Sage Therapeutics (NASDAQ:SAGE) released its earnings results on Thursday. The biopharmaceutical company reported ($1.80) earnings per share for the quarter, missing the consensus estimate of ($1.63) by ($0.17), Briefing.com reports. The business had revenue of $7.90 million for the quarter, compared to the consensus estimate of $5.26 million. Sage Therapeutics had a negative return on equity of 54.41% and a negative net margin of 626.32%. The firm’s revenue for the quarter was up 139.4% compared to the same quarter last year. During the same quarter last year, the business posted ($2.46) earnings per share.

Sage Therapeutics Stock Up 0.8 %

Shares of SAGE traded up $0.11 during mid-day trading on Friday, hitting $13.69. 1,493,679 shares of the company traded hands, compared to its average volume of 1,034,531. The company has a market capitalization of $822.91 million, a PE ratio of -1.53 and a beta of 0.86. The business has a 50 day moving average of $18.75 and a 200 day moving average of $20.68. Sage Therapeutics has a 1-year low of $10.92 and a 1-year high of $59.99.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the stock. StockNews.com lowered shares of Sage Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, April 19th. Needham & Company LLC reaffirmed a “hold” rating on shares of Sage Therapeutics in a research note on Thursday. Mizuho dropped their price objective on Sage Therapeutics from $20.00 to $18.00 and set a “neutral” rating on the stock in a research note on Friday. Royal Bank of Canada decreased their target price on Sage Therapeutics from $26.00 to $15.00 and set a “sector perform” rating for the company in a research report on Friday. Finally, Oppenheimer cut their target price on shares of Sage Therapeutics from $25.00 to $17.00 and set a “market perform” rating on the stock in a research report on Thursday, April 18th. Two research analysts have rated the stock with a sell rating, thirteen have issued a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $37.72.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.